Harvard Bioscience(HBIO)
$8.91-0.48 (-5.11%)
HBIO
Harvard Bioscience financials statements
$8.91
At close:-0.48 (-5.11%)
Want to see HBIO full AI Analyst Report?
Harvard Bioscience (HBIO) Ratios
278 Followers
Harvard Bioscience Ratios
HBIO's free cash flow for Q3 2026 was $-1.18M. For the 2026 fiscal year, HBIO's free cash flow was decreased by $-927.00K and operating cash flow was $-248.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.20 | 0.82 | 1.85 | 2.20 | 2.43 |
| Quick Ratio | 1.25 | 0.40 | 0.92 | 1.06 | 1.34 |
| Cash Ratio | 0.39 | 0.07 | 0.16 | 0.19 | 0.31 |
| Solvency Ratio | -0.77 | -0.09 | 0.06 | -0.03 | 0.09 |
| Operating Cash Flow Ratio | 0.31 | 0.03 | 0.53 | 0.05 | 0.05 |
| Short-Term Operating Cash Flow Coverage | 4.41 | 0.04 | 2.39 | 0.30 | 0.39 |
| Net Current Asset Value | $ -18.11M | $ -18.19M | $ -15.25M | $ -22.02M | $ -17.36M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.55 | 0.35 | 0.31 | 0.37 | 0.35 |
| Debt-to-Equity Ratio | 3.22 | 0.70 | 0.59 | 0.75 | 0.68 |
| Debt-to-Capital Ratio | 0.76 | 0.41 | 0.37 | 0.43 | 0.41 |
| Long-Term Debt-to-Capital Ratio | 0.72 | 0.00 | 0.30 | 0.37 | 0.35 |
| Financial Leverage Ratio | 5.83 | 2.00 | 1.88 | 2.01 | 1.95 |
| Debt Service Coverage Ratio | -7.12 | -0.06 | 0.76 | 0.10 | 1.86 |
| Interest Coverage Ratio | -0.13 | -1.94 | 0.53 | -2.72 | 1.34 |
| Debt to Market Cap | 1.26 | 0.40 | 0.16 | 0.41 | 0.17 |
| Interest Debt Per Share | 11.08 | 10.96 | 1.09 | 1.37 | 1.45 |
| Net Debt to EBITDA | -0.77 | -27.40 | 4.79 | 52.68 | 5.45 |
| Profitability Margins | |||||
| Gross Profit Margin | 53.01% | 58.18% | 58.86% | 53.66% | 56.90% |
| EBIT Margin | -60.62% | -8.98% | 0.92% | -5.85% | 1.18% |
| EBITDA Margin | -53.75% | -1.57% | 7.16% | 0.83% | 7.59% |
| Operating Profit Margin | -0.73% | -6.60% | 1.69% | -6.12% | 1.74% |
| Pretax Profit Margin | -66.30% | -12.39% | -2.28% | -8.10% | -0.12% |
| Net Profit Margin | -65.51% | -13.18% | -3.04% | -8.40% | -0.24% |
| Continuous Operations Profit Margin | -65.51% | -13.18% | -3.04% | -8.40% | -0.24% |
| Net Income Per EBT | 98.80% | 106.34% | 133.61% | 103.67% | 205.71% |
| EBT Per EBIT | 9123.37% | 187.81% | -134.95% | 132.40% | -6.78% |
| Return on Assets (ROA) | -70.81% | -9.80% | -2.49% | -6.55% | -0.18% |
| Return on Equity (ROE) | -412.84% | -19.58% | -4.67% | -13.18% | -0.35% |
| Return on Capital Employed (ROCE) | -1.08% | -8.66% | 1.71% | -5.68% | 1.51% |
| Return on Invested Capital (ROIC) | -1.04% | -5.66% | 1.60% | -5.41% | 1.45% |
| Return on Tangible Assets | -90.18% | -20.96% | -5.31% | -13.98% | -0.37% |
| Earnings Yield | -190.92% | -13.50% | -1.50% | -8.30% | -0.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.39 | 6.33 | 6.97 | 6.78 | 5.45 |
| Payables Turnover | 11.14 | 8.22 | 8.31 | 8.15 | 10.44 |
| Inventory Turnover | 1.95 | 1.69 | 1.87 | 1.99 | 1.86 |
| Fixed Asset Turnover | 18.08 | 8.38 | 12.82 | 12.34 | 11.53 |
| Asset Turnover | 1.08 | 0.74 | 0.82 | 0.78 | 0.73 |
| Working Capital Turnover Ratio | 10.54 | 14.88 | 4.46 | 3.53 | 3.55 |
| Cash Conversion Cycle | 221.61 | 228.77 | 203.81 | 192.75 | 228.51 |
| Days of Sales Outstanding | 67.66 | 57.64 | 52.35 | 53.80 | 67.02 |
| Days of Inventory Outstanding | 186.73 | 215.51 | 195.36 | 183.76 | 196.47 |
| Days of Payables Outstanding | 32.78 | 44.38 | 43.90 | 44.81 | 34.97 |
| Operating Cycle | 254.39 | 273.15 | 247.70 | 237.56 | 263.49 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.52 | 0.33 | 0.33 | 0.03 | 0.03 |
| Free Cash Flow Per Share | 1.26 | -0.42 | 0.28 | -0.01 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 6.04 | 0.44 | 6.07 | 0.72 | 0.94 |
| Capital Expenditure Coverage Ratio | 6.04 | 0.44 | 6.07 | 0.72 | 0.94 |
| Operating Cash Flow Coverage Ratio | 0.15 | 0.03 | 0.33 | 0.02 | 0.02 |
| Operating Cash Flow to Sales Ratio | 0.08 | 0.02 | 0.12 | 0.01 | 0.01 |
| Free Cash Flow Yield | 18.91% | -1.98% | 5.16% | -0.38% | -0.03% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.52 | -7.54 | -66.46 | -12.05 | -987.56 |
| Price-to-Sales (P/S) Ratio | 0.34 | 0.98 | 2.02 | 1.01 | 2.39 |
| Price-to-Book (P/B) Ratio | 2.16 | 1.45 | 3.11 | 1.59 | 3.41 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 5.29 | -50.39 | 19.37 | -261.90 | -3426.72 |
| Price-to-Operating Cash Flow Ratio | 4.41 | 63.80 | 16.18 | 99.58 | 225.37 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.03 | 1.02 | -0.00 | 10.24 |
| Enterprise Value Multiple | -1.40 | -89.72 | 33.04 | 174.20 | 36.98 |
| Enterprise Value | 65.36M | 132.25M | 265.44M | 164.45M | 333.56M |
| EV to EBITDA | -1.40 | -89.72 | 33.04 | 174.20 | 36.98 |
| EV to Sales | 0.76 | 1.40 | 2.36 | 1.45 | 2.81 |
| EV to Free Cash Flow | 11.64 | -72.55 | 22.65 | -375.45 | -4018.76 |
| EV to Operating Cash Flow | 9.71 | 91.84 | 18.92 | 142.75 | 264.31 |
| Tangible Book Value Per Share | -0.78 | -0.95 | -0.00 | -0.12 | -0.04 |
| Shareholders’ Equity Per Share | 3.09 | 14.55 | 1.72 | 1.74 | 2.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | -0.06 | -0.34 | -0.04 | -1.06 |
| Revenue Per Share | 19.50 | 21.62 | 2.65 | 2.74 | 2.95 |
| Net Income Per Share | -12.77 | -2.85 | -0.08 | -0.23 | -0.01 |
| Tax Burden | 0.99 | 1.06 | 1.34 | 1.04 | 2.06 |
| Interest Burden | 1.09 | 1.38 | -2.47 | 1.38 | -0.10 |
| Research & Development to Revenue | 0.10 | 0.11 | 0.10 | 0.11 | 0.09 |
| SG&A to Revenue | 0.43 | 0.46 | 0.20 | 0.22 | 0.20 |
| Stock-Based Compensation to Revenue | -0.02 | 0.05 | 0.04 | 0.04 | 0.04 |
| Income Quality | -0.12 | -0.12 | -4.11 | -0.12 | -4.38 |
Currency in USD

